Digital Health Startups

ExactCare is a pharmacy service that delivers medications to patients' homes while providing ongoing clinical support to optimize medication effectiveness and safety. The company works with insurance providers and doctors to manage patient medications and improve health outcomes.

1 investor

Exalt Health operates inpatient rehabilitation hospitals providing post-acute care and personalized therapy programs for patients recovering from conditions such as stroke, brain and spinal cord injury, joint replacement, and amputation. The Texas-based company runs facilities in states including Texas, Arizona, and Florida.

1 investor

Examedi provides at-home blood tests and telemedicine consultations available 24/7 in Chile. The platform handles insurance reimbursement for users and offers clinical-quality health services at lower costs than traditional in-clinic visits.

1 investor

ExamWorks provides independent medical examinations, peer reviews, bill reviews, and related services through a network of clinics and exam locations. It also undergoes independent financial, healthcare, and security audits and operates as a family of companies.

1 investor

Excelin Health operates care delivery sites across California, Texas, and Louisiana, providing post-acute care services including home health, hospice, and private duty care.

1 investor

Exer.ai is an artificial intelligence company that helps organizations and individuals optimize performance across technical systems, workforce capabilities, and personal development.

1 investor

ExerWatch develops a wearable sensor and companion app that uses AI to learn a patient's prescribed rehabilitation exercise and give real-time feedback on whether each repetition is performed correctly, while sending adherence and technique reports to physiotherapists between visits. The pre-launch product targets physios and rehab patients, and originated from University of Melbourne research.

1 investor

ExMedio provides an IT platform called Hipokura that enables physicians across specialties to share clinical knowledge, seek specialist consultations, and discuss cases to improve diagnostic and treatment quality. The platform serves doctors in Japan with over 70,000 registered physicians and includes specialized consultation features for dermatology, ophthalmology, cardiology, pulmonology, and rare diseases.

1 investor

Exogenus develops therapeutic exosomes derived from umbilical cord blood cells to treat autoimmune diseases through immune system rebalancing. The company targets multiple autoimmune disease indications where existing pharmaceutical treatments carry significant side effects.

1 investor

Experity offers an AI-driven software platform for urgent care businesses, connecting clinical, front desk, and billing workflows across the patient journey. Its products cover EMR and practice management, patient engagement, revenue cycle management, and teleradiology/imaging services.

1 investor

Voxia is a wearable control interface that converts intentional vocal cord activation, such as a hum, into real-time input, allowing people with severe motor and speech impairments (e.g. ALS, stroke, cerebral palsy, Parkinson's) to operate AAC software, computers, tablets, and smart home devices. It is a medical device in development targeting Health Canada and US FDA clearance, aimed at patients who have exhausted conventional access technologies.</parameter> <parameter name="hq_country">CA

1 investor

EXPIN maps the connections between a person's lifetime environmental exposures (their "exposome") and their illness using peer-reviewed research, producing a personalized "expotype" report. It focuses on helping patients with Hashimoto's disease identify likely triggers behind their autoimmune condition to inform testing, treatment, and prevention.

1 investor

ExpiWell provides ecological momentary assessment (EMA) and experience sampling (ESM) software used by researchers to capture real-time data on participants' daily experiences, emotions, and behaviors. The platform enables peer-reviewed research across psychology, medicine, organizational behavior, and ESM methodology.

1 investor

Expressable provides speech therapy services using research-based techniques with a focus on family engagement and accessibility. The company serves families seeking speech-language pathology care for their children.

1 investor

Exprimary develops bioanalytical instrumentation and assay products at reduced cost for research and diagnostic markets. The company focuses on enabling personalized healthcare by improving access to bioanalysis tools globally.

1 investor

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.

1 investor

EyeCheckup is an AI software that analyzes retinal fundus images and OCT scans to screen for and grade more than 20 eye disease pathologies (including diabetic retinopathy, glaucoma, and age-related macular degeneration) as well as cardiovascular and chronic kidney disease. It is designed for eye screening without requiring an expert doctor's opinion or dilating eye drops, and integrates with non-mydriatic fundus cameras.

1 investor

Eye to Eye Telehealth develops technology to address data gaps in glaucoma care, working with engineers and clinicians to improve monitoring and treatment. It focuses on telehealth solutions for glaucoma management.

1 investor

Eyebot provides self-service kiosk technology that measures vision and delivers doctor-written eyeglass prescriptions in minutes for adults aged 18-64. It sells its vision-testing solutions to optical retail brands to expand access to eye care in the United States.

1 investor

EyeBuddy develops AI tools for ophthalmology, including smartphone-based self-screening and detection of conditions such as diabetic retinopathy, cataracts, glaucoma, and keratoconus, plus AI-enhanced video consultations. Its solutions are built with clinical input and tested in hospitals, and it works with eye hospitals and their patients.

1 investor

EyeCheck develops health screening tools that produce an eyeglass prescription automatically, handling refraction and accommodation measurement. The product targets vision care and aims to make refractive error screening more widely accessible.

1 investor

eyeknow.ai offers an AI computer-vision platform that connects to a facility's existing security cameras to detect safety risks such as falls, aggression, and self-harm attempts and alert staff in real time. It targets psychiatric facilities and other care settings to help protect vulnerable patients and document incidents automatically.

1 investor

Eyenuk provides autonomous AI-based eye exams performed at the point of care to detect eye conditions including diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucomatous signs. Its technology holds regulatory clearances such as a Class IIb CE mark under EU MDR and maintains SOC 2 Type 2, HIPAA, and GDPR compliance.

1 investor

Eyetronic develops a non-invasive electrical stimulation therapy and system for patients with progressive visual field loss caused by glaucoma or other optic nerve diseases. The CE-marked therapy applies alternating pulses to stimulate retinal ganglion cell neurons and is offered in selected European treatment centers.

1 investor